Featured Research

from universities, journals, and other organizations

Complete Response With Oblimersen Combination Improves Survival Of CLL Patients

Date:
December 10, 2007
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
Relapsed chronic lymphocytic leukemia (CLL) patients who had a complete response to combination therapy that included the drug oblimersen survived significantly longer than patients treated with chemotherapy alone, a team led by researchers at the University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.

Relapsed chronic lymphocytic leukemia (CLL) patients who had a complete response to combination therapy that included the drug oblimersen survived significantly longer than patients treated with chemotherapy alone, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.

Patients who achieved a complete response with oblimersen have survived so well that a median survival time cannot yet be calculated, but it is estimated to exceed 49 months. Those who achieved complete response with chemotherapy alone had a median survival time of 35 months.

"In a relapsed population, that's excellent survival," says lead author Susan O'Brien, M.D., professor in M. D. Anderson's Department of Leukemia. "Survival is associated with achieving complete response."

The Phase III clinical trial compared a regimen of fludarabine and cyclophosphamide (F/C) with F/C plus oblimersen. Known commercially as Genasense(r), oblimersen blocks the Bcl-2 protein, which plays a critical role in progression of chronic lymphocytic leukemia (CLL), including development of resistance to treatment.

By stifling Bcl-2, researchers believe CLL becomes more vulnerable to chemotherapy such as the F/C combination.

In a paper published in the Journal of Clinical Oncology in March, O'Brien and colleagues showed that patients who received the oblimersen combination were more likely to have a complete response (20 out of 120 patients, or 17 percent, compared to 8 out of 121 patients, 7 percent, who received only the F/C chemotherapy).

Complete response was more durable in the oblimersen-treated patients, with a median duration of at least 36 months compared with 22 months for those on F/C alone.

The question unanswered by the JCO paper was whether this advantage in complete response translated into an advantage in survival, O'Brien says.

Patients were followed for at least three years after randomization or until death or withdrawal from the study. Of the 20 oblimersen-treated patients with a complete response at the end of the first year, 12 survived at least four years. Of the eight complete responders in the other group, four survived at least four years.

The survival data confirm that complete response is a valid endpoint for clinical trials in relapsed or resistant CLL, O'Brien says.

Approval of Genasense(r), produced by Genta, Inc., for CLL is on appeal at the U.S. Food and Drug Administration.

Co-authors with O'Brien are: Joseph Moore, M.D., of Duke University Medical Center; Lily Ding, Ph.D., and Steven Novick, of Genta Inc.; and Kanti Rai, M.D., of Long Island Jewish Medical Center.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Complete Response With Oblimersen Combination Improves Survival Of CLL Patients." ScienceDaily. ScienceDaily, 10 December 2007. <www.sciencedaily.com/releases/2007/12/071210094418.htm>.
University of Texas M. D. Anderson Cancer Center. (2007, December 10). Complete Response With Oblimersen Combination Improves Survival Of CLL Patients. ScienceDaily. Retrieved April 18, 2014 from www.sciencedaily.com/releases/2007/12/071210094418.htm
University of Texas M. D. Anderson Cancer Center. "Complete Response With Oblimersen Combination Improves Survival Of CLL Patients." ScienceDaily. www.sciencedaily.com/releases/2007/12/071210094418.htm (accessed April 18, 2014).

Share This



More Health & Medicine News

Friday, April 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com
Is Apathy A Sign Of A Shrinking Brain?

Is Apathy A Sign Of A Shrinking Brain?

Newsy (Apr. 17, 2014) A recent study links apathetic feelings to a smaller brain. Researchers say the results indicate a need for apathy screening for at-risk seniors. Video provided by Newsy
Powered by NewsLook.com
Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Thousands Of Vials Of SARS Virus Go Missing

Thousands Of Vials Of SARS Virus Go Missing

Newsy (Apr. 16, 2014) A research institute in Paris somehow misplaced more than 2,000 vials of the deadly SARS virus. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins